文献速递消化系统肿瘤

TRAF2在胃癌生物学行为中的作用及机制

[The role and mechanism of TRAF2 in the biological behavior of gastric cancer].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2019-01-01

该研究通过构建TRAF2低表达的胃癌AGS细胞株,发现TRAF2低表达可抑制AGS细胞生长、迁移和侵袭,并降低NF-κB通路RelA、RelB、p50和p52的表达与活性。免疫组化显示胃癌组织TRAF2高表达率为53.0%,高于癌旁组织38.0%,且TRAF2高表达与不良预后相关。

要点

  • TRAF2低表达抑制AGS细胞生长、迁移和侵袭。
  • TRAF2低表达降低NF-κB通路RelA、RelB、p50和p52表达与活性。
  • 胃癌组织TRAF2高表达率为53.0%,与不良预后相关。

核心结论

  • TRAF2低表达可显著抑制胃癌AGS细胞的生长、迁移和侵袭能力。
  • 胃癌组织中TRAF2表达增高,且TRAF2表达与胃癌预后有关。

研究设计与样本

  • 研究构建TRAF2稳定低表达的胃癌AGS细胞株(AGS-siTRAF2),以AGS-sictrl为对照。
  • 采用xCELLigence系统、细胞活力实验、流式细胞术、Transwell、Western blot和TransAM法检测细胞生物学行为及NF-κB通路。
  • 采用免疫组化法检测100例胃癌组织及癌旁组织中TRAF2表达,分析其与临床病理特征及生存的关系。

主要发现

  • 从8 h开始,AGS-siTRAF2细胞生长速度明显慢于AGS-sictrl细胞。
  • 培养24、48和72 h时,AGS-siTRAF2细胞活力A值分别为51 296.00±2 631.06、68 389.25±6 703.21和65 559.50±6 339.22,均显著低于AGS-sictrl细胞(均P<0.001)。
  • 培养24、48和72 h时,AGS-siTRAF2细胞凋亡率分别为(1.42±0.07)%、(2.98±0.11)%和(1.56±0.03)%,均显著高于AGS-sictrl细胞(均P<0.05)。
  • AGS-siTRAF2细胞S期占(23.57±1.12)%,对照组为(19.49±1.19)%,差异有统计学意义(P=0.012)。
  • 培养24 h后,AGS-sictrl迁移细胞数为(121.7±6.7)个,AGS-siTRAF2为(84.0±6.6)个(P=0.002);AGS-sictrl穿膜细胞数为(109.3±3.1)个,AGS-siTRAF2为(79.0±6.2)个(P=0.002)。

关键数值与推荐

  • AGS-siTRAF2细胞中RelA、RelB、p50和p52活性分别为0.01±0.00、0.01±0.01、0.92±0.01和0.53±0.03,均低于AGS-sictrl细胞(均P<0.001)。
  • 100例胃癌组织中TRAF2高表达率为53.0%,癌旁组织为38.0%,差异有统计学意义(P=0.033)。
  • 在管状腺癌、分化程度低、T分期高、N分期高及TNM分期高的胃癌组织中TRAF2高表达率更高(均P<0.05)。
  • TRAF2高表达组和低表达组患者的中位生存时间分别为17和78个月,差异有统计学意义(P=0.010)。

临床怎么用

  • TRAF2在胃癌中高表达并与不良预后相关,可能作为预后评估的参考分子标志物。
  • TRAF2低表达可抑制胃癌细胞生长、迁移和侵袭,提示其可能成为胃癌治疗的潜在靶点。
  • TRAF2作用与NF-κB信号通路相关,为探索胃癌靶向策略提供机制线索。

局限性

  • 研究仅采用AGS一种胃癌细胞株进行体外实验,结论的外推需进一步验证。
  • TRAF2表达与临床病理特征及生存的分析为单中心免疫组化结果,样本量为100例。
  • 原文未报告TRAF2调控NF-κB通路的具体分子机制及体内实验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To clarify the effect of TRAF2 in the biological behavior of gastric cancer and explore the mechanism. Methods: TRAF2 stably depleted AGS cell was established. Cell growth was monitored by x-CELLigence system. Cell proliferation was detected using cell viability assay. The apoptosis and cell cycle were detected by flow cytometry. The difference of migration and invasion abilities were measured by real-time xCELLigence system and Transwell. The expression and activity of NF-κB signaling pathway were measured by western blot and TransAM assay. The expression of TRAF2 in gastric cancer tissue and its clinical significance were detected by immunohistochemistry. Results: The cell index of AGS-siTRAF2 cells was significantly lower than that of AGS-sictrl cells at 8 h. In the cell viability assay, the A values of AGS-siTRAF2 cells were 51 296.00±2 631.06, 68 389.25±6 703.21 and 65 559.50±6 339.22 at 24 h, 48 h and 72 h. The values of the viability of AGS-siTRAF2 cells were significantly lower than those of AGS-sictrl cells (P<0.001). The results of flow cytometry showed that the apoptosis rates of AGS-siTRAF2 cells were (1.42±0.07)%, (2.98±0.11)% and (1.56±0.03)% at 24 h, 48 h and 72 h, respectively, which were significantly higher than those of AGS-sictrl cells (all P<0.05). The distribution of S phase in AGS-siTRAF2 cells was (23.57±1.12)%, while that in the AGS-sictrl cells was (19.49±1.19)%. The difference was statistically significant (P=0.012). AGS-siTRAF2 cells migrated much slower than AGS-sictrl cells from 3 h and the number of migrated AGS-sictrl cells was 121.7±6.7 while that of AGS-siTRAF2 cells was 84.0±6.6 (P=0.002). The cell index of AGS-siTRAF2 cells was less than that of AGS-sictrl cells from 3 h. In Transwell assay, the number of invaded AGS-sictrl cells was 109.3±3.1 after 24 h of culture, significantly higher than 79.0±6.2 of AGS-siTRAF2 cells (P=0.002). Western blot analysis showed that the expression levels of RelA, RelB, p50 and p52 in AGS-siTRAF2 cells were significantly lower than those in AGS-sictrl cells. The activities of RelA, RelB, p50 and p52 in AGS-siTRAF2 cells were 0.01±0.00, 0.01±0.01, 0.92±0.01 and 0.53±0.03, respectively, significantly lower than those of AGS-sictrl cells (all P<0.001). High TRAF2 expression (TRAF2-high) was found in 53.0% of GC samples, while TRAF2-high was only observed in 38.0% of the paired adjacent tissues (P=0.033). The expression of TRAF2 was significantly higher in the tubular adenocarcinoma, poor differentiation advanced T, advanced N, and clinical staging (P<0.05). The median survival time were 17 months and 78 months in the TRAF2 high-expression and low-expression groups, respectively, and the difference was statistically significant (P=0.010). Conclusions: Depletion of TRAF2 inhibits the AGS cell growth, migration and invasion. The expression of TRAF2 is increased in gastric tumor tissue. The expression of TRAF2 is associated with the prognosis of gastric cancer. 目的: 探讨肿瘤坏死因子受体相关因子2(TRAF2)对胃癌AGS细胞生长、迁移和侵袭等细胞生物学行为的影响及机制。 方法: 构建低表达TRAF2的胃癌AGS细胞株(AGS-siTRAF2),采用xCELLigence系统和细胞活力实验检测细胞的生长和增殖情况。采用流式细胞术检测细胞凋亡和细胞周期,采用xCELLigence系统和Transwell实验检测细胞的迁移和侵袭能力。采用Western blot法和TransAM法检测低表达TRAF2对AGS细胞核转录因子κB(NF-κB)信号通路的影响。采用免疫组化法检测胃癌组织中TRAF2的表达,分析TRAF2表达与胃癌临床病理特征的关系和对患者生存的影响。 结果: xCELLigence系统动态检测结果显示,从8 h开始,AGS-siTRAF2细胞的生长速度明显慢于AGS-sictrl细胞。细胞活力实验显示,培养24、48和72 h时,AGS-siTRAF2细胞的吸光度(A)值分别为51 296.00±2 631.06、68 389.25±6 703.21和65 559.50±6 339.22,均显著低于AGS-sictrl细胞(均P<0.001)。流式细胞术检测结果显示,培养24、48和72 h时,AGS-siTRAF2细胞凋亡率分别为(1.42±0.07)%、(2.98±0.11)%和(1.56±0.03)%,均显著高于AGS-sictrl细胞(均P<0.05);AGS-siTRAF2细胞S期占(23.57±1.12)%,对照组为(19.49±1.19)%,差异有统计学意义(P=0.012)。xCELLigence系统检测显示,从3 h开始,AGS-siTRAF2细胞的迁移能力低于AGS-sictrl细胞。Transwell实验检测结果显示,培养24 h后,AGS-sictrl的细胞数为(121.7±6.7)个,AGS-siTRAF2的细胞数为(84.0±6.6)个,AGS-siTRAF2细胞的迁移细胞数明显少于AGS-sictrl细胞(P=0.002)。xCELLigence系统检测结果显示,从3 h开始,AGS-siTRAF2细胞的细胞指数低于AGS-sictrl细胞。Transwell实验检测结果显示,培养24 h,AGS-sictrl的细胞数为(109.3±3.1)个,AGS-siTRAF2的细胞数为(79.0±6.2)个,AGS-siTRAF2细胞的穿膜细胞数明显少于AGS-sictrl细胞(P=0.002)。Western blot检测结果显示,AGS-siTRAF2细胞中RelA、RelB、p50和p52表达水平均明显低于AGS-sictrl细胞。TransAM检测结果显示,AGS-siTRAF2细胞中RelA、RelB、p50和p52的活性分别为0.01±0.00、0.01±0.01、0.92±0.01和0.53±0.03,均低于AGS-sictrl细胞(均P<0.001)。100例胃癌组织中TRAF2高表达率为53.0%,高于癌旁组织(38.0%),差异有统计学意义(P=0.033)。在管状腺癌、分化程度低、T分期高、N分期高及TNM分期高的胃癌组织中TRAF2高表达率更高(均P<0.05)。TRAF2高表达组和低表达组患者的中位生存时间分别为17和78个月,差异有统计学意义(P=0.010)。 结论: TRAF2低表达能显著抑制胃癌AGS细胞的生长、迁移和侵袭能力。胃癌组织中TRAF2的表达增高,TRAF2的表达与胃癌的预后有关。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Dai HJ, Xu JJ, Li WJ, et al. [The role and mechanism of TRAF2 in the biological behavior of gastric cancer]. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 31770846. doi:10.3760/cma.j.issn.0253-3766.2019.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。